We found that patients with glioma and lower expression of TRIB2 or MAP3K1 exhibited prolonged overall survival compared with patients with glioma and higher TRIB2 or MAP3K1 expression (Figure 7A,B). This evidence concerns the gene TRIB2 and central nervous system cancer.